ACTRN12612001082897已完成不适用
Does rosuvastatin delay progression of atherosclerosis in people with HIV infection at moderate cardiovascular risk? A randomized, placebo-controlled trial
Jennifer Hoy0 个研究点目标入组 85 人开始时间: 2012年10月9日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 85
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Adults with proven HIV infection who are on a stable combination anti-retroviral therapy regimen with a plasma HIV viral load < 200 copies/ml for > six months AND
- •who are at moderate cardiovascular risk , as estimated by a Framingham Risk score of 10-15% 10 year risk of cardiovascular disease
排除标准
- •- Fullfilling any current indication for lipid lowering therapy
- •- Any contraindication to rosuvastatin therapy (including previous allergy, pregnancy, myopathy, creatinine clearance <30ml/min)
- •- Use of contraindicated concurrent medications (cyclosporine, Gemfibrozil, Niacin, Fusidic acid)
研究者
相似试验
已完成
4 期
Effect of drug rosuvastatin in females with type 2 diabetes mellitusCTRI/2018/07/014844Sri Venkateswara Institute of Medical Sciences29
已完成
4 期
Effect of the drug Rosuvastatin in lowering the risk of heart disease in diabetes patientsCTRI/2017/09/009695Sri Venkateswara Institute of Medical Sciences40
进行中（未招募）
1 期
Statin effect on atheroma calcificatioAtherosclerosis, namely in the aorta, carotid and coronary arteriesEUCTR2018-003837-13-PTCentro Hospitalar e Universitário de Coimbra, E.P.E.44
已完成
4 期
Does Rosuvastatin Delay Progression of Atherosclerosis in HIVHIVCardiovascular DiseaseNCT01813357Bayside Health84
进行中（未招募）
不适用
Effect of rosuvastatin on cardiovascular events and mortality after pneumoniaCommunity aquired pneumoniaEUCTR2007-004894-25-SEKarolinska University Hospital Huddinge